Trial Search Results

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Andrei Iagaru

Collaborator: National Institutes of Health (NIH)

Stanford Investigator(s):


  • Drug: 68-Ga RM2.
  • Drug: 68-Ga PSMA11
  • Device: PET/MRI


Phase 2


Inclusion Criteria:

   - Patients must be at least 18 years of age;

   - Patients must be able to provide informed consent;

   - Histologically proven low-grade or intermediate-grade prostate cancer (PC)

   - Scheduled to undergo targeted local therapy (HDR brachytherapy).

Exclusion Criteria:

   - Inability to lie still for the entire imaging time;

   - Inability to complete the needed investigational and standard-of-care imaging
   examinations due to other reasons (severe claustrophobia, radiation phobia, etc.);

   - Any additional medical condition, serious intercurrent illness, or other extenuating
   circumstance that, in the opinion of the Investigator, may significantly interfere
   with study compliance;

   - Metallic implants (contraindicated for MRI).

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Risa Jiron
Not Recruiting